BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 2, 2026
Home
»
Newsletters
» BioWorld
BioWorld
June 7, 2004
View Archived Issues
Myriad's Stock Sale Gets $50.2M To Move Flurizan Through Clinic
Read More
Inhibitex Gains $35M After Dropping IPO Share Price
Read More
FDA Satisfied With Rat Data; Dyax Phase II Trials Resume
Read More
SeraCare Paying $14.3M To Buy Genomics Collaborative
Read More
Other News To Note
Read More
Correction
Read More
CuraGen, TopoTarget Form HDAC Inhibitor Deal Worth Up To $100M
As it transforms itself from a genomics discovery company to a product development company, CuraGen Corp. in-licensed a promising cancer compound from the Danish firm TopoTarget A/S. (BioWorld Today)
Read More
More Global Attendees Flock To Industry's Annual Meeting
Read More
